
Jordan R Covvey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8575979/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical use of lefamulin: A firstâ€inâ€class semisynthetic pleuromutilin antibiotic. Journal of Internal Medicine, 2022, 291, 51-63.	6.0	4
2	A Systematic Review of Global Health Assessment for Education in Healthcare Professions. Annals of Global Health, 2022, 88, 1.	2.0	10
3	Xylazine poisoning: a systematic review. Clinical Toxicology, 2022, 60, 892-901.	1.9	23
4	Safety and efficacy of cefiderocol for offâ€label treatment indications: A systematic review. Pharmacotherapy, 2022, 42, 549-566.	2.6	6
5	Gabapentin initiation in the inpatient setting: A characterization of prescribing. American Journal of Health-System Pharmacy, 2022, 79, S65-S73.	1.0	1
6	The Relationship between Knowledge, Attitudes, and Practices of Community Pharmacists Regarding Persons with Substance use Disorders. Substance Abuse, 2021, 42, 630-637.	2.3	12
7	Patient Satisfaction with Substance Use Disorder Rehabilitation Services: a Qualitative Study. Journal of Behavioral Health Services and Research, 2021, 48, 213-239.	1.4	2
8	Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs, 2021, 81, 125-156.	10.9	94
9	Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. International Journal of Clinical Pharmacy, 2021, 43, 1055-1064.	2.1	17
10	Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review. International Journal of Clinical Practice, 2021, 75, e13991.	1.7	2
11	Letter to the Editor: Comment on "Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth†Pain and Therapy, 2021, 10, 751-755.	3.2	1
12	Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update― Drugs, 2021, 81, 615-617.	10.9	3
13	Safety and Efficacy of Rivaroxaban and Apixaban in Patients with Increased Body Mass: a Systematic Review. Clinical Drug Investigation, 2021, 41, 353-369.	2.2	9
14	Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database. Journal of Drug Assessment, 2021, 10, 62-67.	2.2	15
15	Clinical outcomes of concomitant rifamycin and opioid therapy: A systematic review. Pharmacotherapy, 2021, 41, 479-489.	2.6	1
16	Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability. Journal of Clinical Pharmacology, 2021, 61, S89-S99.	2.0	15
17	Pharmacist Views Regarding the Prescription Opioid Epidemic. Substance Use and Misuse, 2021, 56, 1-10.	1.4	7
18	But Scholarship Can Be Hard in Many Ways. American Journal of Pharmaceutical Education, 2021, 85, 8620.	2.1	1

Jordan R Covvey

#	Article	IF	CITATIONS
19	The impact of clinical pharmacy services on pneumococcal vaccine frequency and appropriateness in a family medicine clinic. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 362-367.	1.5	2
20	Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target–Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. Annals of Pharmacotherapy, 2020, 54, 644-651.	1.9	15
21	Prevalence and characteristics of self-reported kratom use in a representative US general population sample. Journal of Addictive Diseases, 2020, 38, 506-513.	1.3	33
22	The impact of a pharmacist-led naloxone education and community distribution project on local use of naloxone. Journal of the American Pharmacists Association: JAPhA, 2020, 60, S56-S60.	1.5	10
23	Type II interferon signaling in the brain during a viral infection with ageâ€dependent pathogenesis. Developmental Neurobiology, 2020, 80, 213-228.	3.0	2
24	National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. Journal of Substance Abuse Treatment, 2020, 119, 108141.	2.8	3
25	Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States. Substance Abuse: Research and Treatment, 2020, 14, 117822181989458.	0.9	1
26	Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Research in Social and Administrative Pharmacy, 2019, 15, 953-958.	3.0	70
27	Pharmaceutical care in transplantation: current challenges and future opportunities. Nanomedicine, 2019, 14, 2651-2658.	3.3	2
28	Evolution of the review article: An expansion of publication opportunities in JAPhA. Journal of the American Pharmacists Association: JAPhA, 2019, 59, 767-768.	1.5	1
29	Barriers and facilitators to shared decision-making in oncology: a systematic review of the literature. Supportive Care in Cancer, 2019, 27, 1613-1637.	2.2	96
30	PMH61 PATIENT SATISFACTION IN SUBSTANCE USE DISORDER TREATMENT: A SYSTEMATIC LITERATURE REVIEW. Value in Health, 2019, 22, S236-S237.	0.3	0
31	Prescribing trends and revisit rates following a pharmacist-driven protocol change for community-acquired pneumonia in an emergency departmentâ€. International Journal of Pharmacy Practice, 2019, 27, 279-285.	0.6	6
32	The relationship between a cirrhosisâ€specific comorbidity scoring system and healthcare utilization patterns. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1222-1230.	2.8	0
33	Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. Expert Review of Anti-Infective Therapy, 2019, 17, 5-15.	4.4	21
34	Development of a Statewide Antibiogram to Assess Regional Trends in Antibiotic-Resistant ESKAPE Organisms. Journal of Pharmacy Practice, 2019, 32, 19-27.	1.0	11
35	Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population. Pharmacotherapy, 2018, 38, 436-443.	2.6	37
36	Use of a Modified Delphi Process to Determine Course Objectives for a Model Global Health Course in a Pharmacy Curriculum. American Journal of Pharmaceutical Education, 2018, 82, 6358.	2.1	17

JORDAN R COVVEY

#	Article	IF	CITATIONS
37	The effect of body weight on intravenous diltiazem in patients with atrial fibrillation with rapid ventricular response. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 855-859.	1.5	3
38	Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?. Substance Abuse: Research and Treatment, 2018, 12, 117822181880131.	0.9	42
39	Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 987-997.	0.9	3
40	Community pharmacists and mental illness: a survey of service provision, stigma, attitudes and beliefs. International Journal of Clinical Pharmacy, 2018, 40, 1096-1105.	2.1	34
41	Knowledge, attitudes and beliefs regarding human immunodeficiency virus and in-home testing among a regional sample of student pharmacists. Currents in Pharmacy Teaching and Learning, 2017, 9, 980-988.	1.0	4
42	A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 136-162.	0.9	47
43	Development and Implementation of a Global Health Elective with a Drug Discovery Game for Pharmacy Students. Pharmacy (Basel, Switzerland), 2017, 5, 49.	1.6	8
44	Development of an obstetrics triage tool for clinical pharmacists. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 539-544.	1.5	11
45	U.S. Pharmacist Opinions Regarding the Rescheduling of Hydrocodone Combination Products: A Pilot Study. Pharmacy (Basel, Switzerland), 2015, 3, 129-136.	1.6	2
46	Antimicrobial-related medication safety incidents: a regional retrospective study in West of Scotland hospitals. Journal of Hospital Infection, 2015, 91, 264-270.	2.9	2
47	Recent developments toward the safer use of opioids, with a focus on hydrocodone. Research in Social and Administrative Pharmacy, 2015, 11, 901-908.	3.0	12
48	Examining Pharmacy Workforce Issues in the United States and the United Kingdom. American Journal of Pharmaceutical Education, 2015, 79, 17.	2.1	17
49	Changes to inhaled corticosteroid dose when initiating combination inhaler therapy in long-acting β agonist-naÃ⁻ve patients with asthma: a retrospective database analysis. Thorax, 2014, 69, 1056-1058.	5.6	6
50	A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. International Journal of Clinical Practice, 2014, 68, 1200-1208.	1.7	44
51	Pursuing a training experience abroad. American Journal of Health-System Pharmacy, 2014, 71, 904-907.	1.0	0
52	An association between socioeconomic deprivation and primary care antibiotic prescribing in Scotland. Journal of Antimicrobial Chemotherapy, 2014, 69, 835-841.	3.0	58
53	Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2014, 48, 1611-1619.	1.9	14
54	Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapy. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 290-295.	2.3	10

JORDAN R COVVEY

#	Article	IF	CITATIONS
55	Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder. Annals of Pharmacotherapy, 2012, 46, 117-123.	1.9	44
56	Management of medication use in Scotland. American Journal of Health-System Pharmacy, 2010, 67, 1378-1382.	1.0	1
57	Glimepiride-Induced Hypoglycemia with Ciprofloxacin, Metronidazole, and Acute Kidney Injury. Hospital Pharmacy, 2010, 45, 934-938.	1.0	4
58	Impact of a cardiology pharmacistâ€led intervention on highâ€intensity statin prescribing upon discharge after acute myocardial infarction. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	0